Geron Completes $75 Million Follow-On Offering

Healthcare

Geron follow-on offering


Summary

Geron Corporation (“Geron”) (NASDAQ:GERN) recently completed an underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of its common stock, together with accompanying warrants, to purchase 35,714,286 shares of its common stock. The combined offering price to the public of each share of common stock and accompanying warrant was $1.05. The combined offering price to the public of each pre-funded warrant and accompanying warrant was $1.049. The common stock and pre-funded warrants were sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The gross proceeds to Geron from the offering were approximately $75 million, before deducting underwriting discount and estimated offering expenses.

Baird served as an active bookrunner on this offering.

About

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. Geron is currently conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. Geron Corporation is headquartered in Foster City, California.
CONTACT US TO LEARN MORE
Healthcare

Geron follow-on offering

Date
April 2022
Company
Geron Corporation
Transaction
Equity Capital Markets
Sectors
Healthcare
Verticals
Biotechnology & Pharmaceuticals
Target Geography
North America

Share